{
    "nctId": "NCT04239105",
    "briefTitle": "Detection of Circulating Tumor Cells in Breast Cancer Patients Using a Novel Microfluidic and Raman Spectrum Device",
    "officialTitle": "Detection and Analysis of Circulating Tumor Cells (CTCs) in Patients With Breast Cancer Using a Novel Microfluidic and Raman Spectrum Device",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Neoplasms, Circulating Tumor Cells",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 120,
    "primaryOutcomeMeasure": "The level of CTC markers in breast cancer patients' peripheral blood",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* All subjects need to sign the informed consent form.\n* Age of at least 20 and at most 70 years.\n* Cancer group subjects with pathology report confirmed to be malignant.\n* Chemotherapy is necessary before or after surgery.\n* Control group need to have mammogram /ultrasound results category1-3.\n* Patients must be available for and compliant to treatment and follow-up.\n\nExclusion Criteria:\n\n* Not willing to sign the informed consent form.\n* Pregnant or lactating patients.\n* Prior or concomitant secondary malignancy.\n* Any other serious medical pathology, such as congestive heart failure.\n* Other condition which may affect the CTC results.\n* Males.",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}